Trial Profile
A trial to evaluate effectiveness of 6-months pasireotide treatment on clinical and hormonal profiles in a group of cushing's disease patients with mild to moderate disease according with the real-word evidence.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jun 2020
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary)
- Indications Pituitary ACTH hypersecretion
- Focus Therapeutic Use
- 02 Jun 2016 New trial record
- 04 Apr 2016 Results presented at The 98th Annual Meeting of the Endocrine Society